文献速递消化道肿瘤放疗

血浆丝氨酸与甘氨酸比值与直肠癌新辅助放疗后临床结局的关系

Plasma serine and glycine in relation to clinical outcomes following neoadjuvant radiotherapy for rectal cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-04-06

基于288例I-III期直肠癌前瞻性队列,诊断期采集血样用GC-MS/MS测血浆丝氨酸和甘氨酸。丝氨酸、甘氨酸及其比值与肿瘤降期无关;丝氨酸/甘氨酸比值较高与癌症复发风险降低相关(每倍增HR 0.47,95%CI 0.22-0.99),肿瘤降期与复发风险降低相关(HR 0.40,95%CI 0.22-0.70)。

要点

  • 丝氨酸、甘氨酸及其比值与直肠癌新辅助治疗后肿瘤降期无关联。
  • 丝氨酸/甘氨酸比值每倍增与复发风险降低相关(HR 0.47,95%CI 0.22-0.99)。
  • 肿瘤降期者复发风险更低(HR 0.40,95%CI 0.22-0.70)。

核心结论

  • 首次发现丝氨酸/甘氨酸比值(反映SHMT酶活性)与直肠癌复发可能存在关联。
  • 需进一步研究确认该发现并探究生物学机制及靶向SHMT酶活性的治疗策略。

研究设计与样本

  • 基于前瞻性队列研究,纳入288例I-III期直肠癌患者。
  • 诊断前后采集血样,采用GC-MS/MS测定血浆丝氨酸和甘氨酸水平。
  • 肿瘤降期定义为新辅助治疗后T分期下降(pT < cT),复发包括术后5年内局部区域复发和远处转移。
  • 采用回归模型计算肿瘤降期和复发的相对风险(RR)与风险比(HR)及其95%CI。

主要发现

  • 41%(n=117)患者出现肿瘤降期,5年复发率为23%(n=67)。
  • 丝氨酸、甘氨酸及其比值与肿瘤降期无关联。
  • 丝氨酸/甘氨酸比值较高与癌症复发风险降低相关(每倍增HR 0.47,95%CI 0.22-0.99)。
  • 肿瘤降期与癌症复发风险降低相关(HR 0.40,95%CI 0.22-0.70)。

关键数值与推荐

  • 肿瘤降期判定标准:新辅助治疗后pT < cT。
  • 复发定义:术后5年内发生的局部区域复发和远处转移。
  • 丝氨酸/甘氨酸比值每倍增的复发HR为0.47(95%CI 0.22-0.99)。
  • 肿瘤降期者的复发HR为0.40(95%CI 0.22-0.70)。

临床怎么用

  • 血浆丝氨酸/甘氨酸比值可能作为直肠癌新辅助治疗后复发风险的潜在生物标志物。
  • 肿瘤降期与更低复发风险相关,支持将降期作为预后评估指标。
  • 目前尚不能基于该比值调整临床决策,需进一步验证。

局限性

  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is substantial variation in radiotherapy response among patients with rectal cancer. The amino acids serine and glycine have been proposed as radiosensitizers in preclinical studies. Here, we explored associations between plasma serine, glycine, and their ratio and clinical outcomes following neoadjuvant treatment for rectal cancer, including tumour downstaging and cancer recurrence. METHODS: Based on a prospective cohort study, 288 patients with stage I-III rectal cancer were included. Blood was collected around diagnosis and plasma levels of serine and glycine were measured using GC-MS/MS. Tumour downstaging was defined as T-classification downstaging (pT < cT) after neoadjuvant treatment and recurrence included locoregional recurrences and distant metastases occurring in the 5-years after surgery. Regression models were used to calculate relative risks (RR) and hazard ratios (HR) and their 95% confidence intervals (CI) for tumour downstaging and recurrence, respectively. RESULTS: Tumour downstaging was observed in 41% (n = 117) of the patients and the 5-year recurrence rate was 23% (n = 67). Serine, glycine, and their ratio were not associated with tumour downstaging. A higher serine/glycine ratio was associated with a lower risk of cancer recurrence (HRperdoubling 0.47, 95%CI 0.22-0.99) and tumour downstaging was associated with lower risk of cancer recurrence (HR 0.40, 95%CI 0.22-0.70). CONCLUSION: This is the first study demonstrating a potential association between the serine/glycine ratio, an indicator of SHMT enzyme activity, and rectal cancer recurrence. Further studies are warranted to confirm these findings, as well as investigate underlying biological mechanisms and potentially explore strategies to target SHMT enzyme activity in the context of cancer treatment.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zwart NRK, Ueland PM, McCann A, et al. Plasma serine and glycine in relation to clinical outcomes following neoadjuvant radiotherapy for rectal cancer. Clin Transl Radiat Oncol. 2026. PMID: 42005714. doi:10.1016/j.ctro.2026.101159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。